Anhui Fengyuan Pharmaceutical Co., Ltd. Wuwei Pharmaceutical Factory
Published:
2018-08-07
Source:
Author:
The predecessor of Anhui Fengyuan Pharmaceutical Co., Ltd. was founded in the 1970s. After half a century of development, it has now become a large pharmaceutical enterprise integrating pharmaceutical research and development, production and sales. In 2000, the company was listed on the Shenzhen Stock Exchange (stock code: 000153), and has been listed in China's top 100 pharmaceutical industry since 2007. It is a pilot enterprise for system implementation and a Chinese innovative pharmaceutical enterprise in 2015. The company's total assets are 2.274 billion yuan and more than 4,700 employees. The company has 15 subsidiaries including pharmaceutical production, pharmaceutical marketing, large pharmacy chain and 1 nationally recognized enterprise technology center.
In 2020, the company's main income is 3.3 billion yuan, and the tax payment is 227 million yuan; in 2021, the company's main income is about 3.5 billion yuan, and the tax payment is about 220 million yuan. Among them, Wuwei Pharmaceutical will achieve sales revenue of 438 million yuan in 2020 and pay taxes of 44.4 million yuan; in 2021, it will achieve sales revenue of 350 million yuan and pay taxes of about 26 million yuan.
Wuwei Pharmaceutical Factory mainly produces electrolyte infusions, amino acid series injections, fat emulsion series injections, fructose injections, polygelatin injections, lomefloxacin, metronidazole, mannitol and other 61 varieties of multi-specification infusions preparation. Among them, the national sales volume of fat emulsion series injection and fructose injection ranks first.
In 2012, Wuwei Pharmaceutical Factory responded to the call of Wuwei County Party Committee and County Government to "delist and enter the park", and started construction in Wuwei County Economic Development Zone in April 2013. The first phase of the project invested 268 million yuan and resumed the original annual production. The capacity of infusion is 200 million bottles/bag, and the relocation of the whole plant was successfully completed in January 2017. Along with the construction of the new plant, focus on strengthening the adjustment of product structure, increasing the development of therapeutic and nutritional varieties, the current development idea is to create "specialized, refined and new" varieties, and two varieties of fat emulsion series are being clinically and developed; In order to solve the difficulty of hemodialysis for uremia patients, a new peritoneal dialysis solution project of 220 million yuan has been completed. It is expected that the product will be launched in 2023, and will achieve an additional sales income of 200 million yuan and a tax of 20 million yuan; the third is to optimize the company's resources It is planned to build Wuwei Pharmaceutical Factory into a preparation production base of Fengyuan Pharmaceutical in the future.
Fengyuan Pharmaceutical has always adhered to the tenet of "reproducing green life and caring for human health", and has made unremitting efforts to achieve national interests, corporate interests and employee interests.
Related Information
2022-06-30

2022-06-30

2022-06-30
